Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $541.55, for a total value of $4,494,865.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,462,896.60. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Price Performance

United Therapeutics stock opened at $536.59 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market capitalization of $22.78 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. The business’s fifty day moving average is $564.47 and its 200 day moving average is $523.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 earnings per share. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter valued at about $31,000. International Assets Investment Management LLC increased its position in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UTHR. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.